EMA Recommends Extension of Therapeutic Indications for Retifanlimab By Ogkologos - February 6, 2026 426 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with squamous cell carcinoma of the anal canal Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Pump Up the Volume: “Priming Agents” May Improve Cancer Liquid Biopsies February 22, 2024 How My Advanced Colorectal Cancer Diagnosis Led Me to Patient Advocacy March 3, 2021 What to Know About Peer-Reviewed Cancer Information and Its Role in... August 10, 2022 Genomic Alterations Enriched in Young Women with HR-positive, HER2-negative Early Breast... February 9, 2023 Load more HOT NEWS ΟΡΘΟΚΟΛΙΚΟΣ ΚΑΡΚΙΝΟΣ Could A Diabetes Diagnosis Help Detect Pancreatic Cancer Early? FDA Grants Accelerated Approval to Mirvetuximab Soravtansine-gynx for FRα-Positive, Platinum-Resistant Epithelial... Inside Cancer Grand Challenges Part 1: what makes a grand challenge?
